Stock listing
Frankfurt:8ZD Abbisko Cayman Limited Aktie
German listing (Frankfurt) of Abbisko Cayman Limited · home listing HKEX:2256
Follow Abbisko Cayman Limited into a list and get an email when it puts out news.
Share price · FWB:8ZD
€0.695 EUR -0.010 (-1.4%)
Close on Nov 20, 2026
- Day range
- €0.645 – €0.695 EURNov 20, 2026
- Market cap
- €497.7M EURAt the close on Nov 20, 2026 · price × 716.2M shares outstanding
- 52-week range
- €0.645 – €1.621 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1,151 EURMedian day 0 shares · 54 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2256 · Home | $5.68 HKD | -0.62 (-9.8%) | 2,641,000 | $6.065 | $6.065 | $5.64 | $6.30 | Close on Nov 20, 2026 |
| Frankfurt:8ZD | €0.695 EUR | -0.010 (-1.4%) | — | €0.655 | €0.695 | €0.645 | €0.705 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:8ZD · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.706 | -0.073 | -9.4% | €0.711 | €0.719 | €0.705 | 0 | |
| €0.779 | +0.040 | +5.4% | €0.779 | €0.784 | €0.777 | 0 | |
| €0.739 | +0.059 | +8.7% | €0.743 | €0.744 | €0.739 | 0 | |
| €0.680 | -0.050 | -6.8% | €0.689 | €0.696 | €0.670 | 27,200 | |
| €0.730 | +0.031 | +4.4% | €0.715 | €0.740 | €0.704 | 0 | |
| €0.699 | -0.020 | -2.8% | €0.699 | €0.699 | €0.699 | 44,000 | |
| €0.719 | -0.024 | -3.2% | €0.718 | €0.721 | €0.715 | 0 | |
| €0.743 | +0.003 | +0.4% | €0.743 | €0.743 | €0.743 | 22,000 | |
| €0.740 | -0.036 | -4.6% | €0.740 | €0.740 | €0.734 | 0 | |
| €0.776 | +0.007 | +0.9% | €0.776 | €0.776 | €0.776 | 0 | |
| €0.769 | -0.021 | -2.7% | €0.778 | €0.784 | €0.766 | 0 | |
| €0.790 | -0.053 | -6.3% | €0.792 | €0.803 | €0.782 | 0 | |
| €0.843 | -0.005 | -0.6% | €0.839 | €0.857 | €0.835 | 0 | |
| €0.848 | -0.013 | -1.5% | €0.850 | €0.860 | €0.845 | 0 | |
| €0.861 | -0.005 | -0.6% | €0.857 | €0.864 | €0.851 | 0 | |
| €0.866 | +0.047 | +5.7% | €0.861 | €0.874 | €0.860 | 0 | |
| €0.819 | -0.022 | -2.6% | €0.819 | €0.820 | €0.819 | 0 | |
| €0.841 | -0.019 | -2.2% | €0.841 | €0.841 | €0.841 | 0 | |
| €0.860 | -0.001 | -0.1% | €0.865 | €0.876 | €0.860 | 0 | |
| €0.861 | -0.024 | -2.7% | €0.868 | €0.870 | €0.860 | 0 | |
| €0.885 | -0.019 | -2.1% | €0.890 | €0.890 | €0.881 | 0 | |
| €0.904 | -0.055 | -5.7% | €0.911 | €0.911 | €0.903 | 0 | |
| €0.959 | -0.045 | -4.5% | €0.968 | €0.972 | €0.959 | 0 | |
| €1.004 | +0.017 | +1.7% | €1.004 | €1.004 | €1.004 | 0 | |
| €0.987 | +0.007 | +0.7% | €0.981 | €0.988 | €0.981 | 0 | |
| €0.980 | -0.024 | -2.4% | €0.976 | €0.987 | €0.974 | 0 | |
| €1.004 | +0.011 | +1.1% | €1.009 | €1.009 | €0.999 | 0 | |
| €0.993 | +0.023 | +2.4% | €0.989 | €0.999 | €0.981 | 0 | |
| €0.970 | +0.002 | +0.2% | €0.974 | €0.986 | €0.967 | 0 | |
| €0.968 | -0.017 | -1.7% | €0.968 | €0.968 | €0.968 | 0 | |
| €0.985 | -0.007 | -0.7% | €0.987 | €1.000 | €0.985 | 0 | |
| €0.992 | -0.036 | -3.5% | €0.992 | €0.992 | €0.992 | 0 | |
| €1.028 | +0.024 | +2.4% | €1.028 | €1.028 | €1.028 | 0 | |
| €1.004 | +0.018 | +1.8% | €1.021 | €1.026 | €1.004 | 0 | |
| €0.986 | +0.057 | +6.1% | €0.984 | €0.988 | €0.980 | 0 | |
| €0.929 | +0.023 | +2.5% | €0.929 | €0.936 | €0.928 | 0 | |
| €0.906 | +0.003 | +0.3% | €0.912 | €0.914 | €0.905 | 0 | |
| €0.903 | -0.038 | -4.0% | €0.903 | €0.903 | €0.903 | 0 | |
| €0.941 | +0.008 | +0.9% | €0.929 | €0.947 | €0.923 | 0 | |
| €0.933 | +0.011 | +1.2% | €0.938 | €0.942 | €0.931 | 0 | |
| €0.922 | +0.010 | +1.1% | €0.927 | €0.935 | €0.917 | 0 | |
| €0.912 | -0.040 | -4.2% | €0.912 | €0.912 | €0.912 | 0 | |
| €0.952 | -0.003 | -0.3% | €0.956 | €0.958 | €0.950 | 0 | |
| €0.955 | -0.013 | -1.3% | €0.962 | €0.962 | €0.953 | 0 | |
| €0.968 | +0.009 | +0.9% | €0.972 | €0.972 | €0.951 | 0 | |
| €0.959 | -0.016 | -1.6% | €0.967 | €0.968 | €0.959 | 0 | |
| €0.975 | +0.002 | +0.2% | €0.977 | €0.982 | €0.975 | 0 | |
| €0.973 | +0.031 | +3.3% | €0.974 | €0.974 | €0.971 | 0 | |
| €0.942 | -0.062 | -6.2% | €0.969 | €0.977 | €0.942 | 0 | |
| €1.004 | +0.002 | +0.2% | €0.968 | €1.004 | €0.967 | 0 | |
| €1.002 | -0.067 | -6.3% | €1.002 | €1.003 | €1.002 | 0 | |
| €1.069 | +0.001 | +0.1% | €1.071 | €1.072 | €1.069 | 0 | |
| €1.068 | -0.002 | -0.2% | €1.070 | €1.070 | €1.065 | 0 | |
| €1.070 | -0.001 | -0.1% | €1.059 | €1.073 | €1.055 | 0 | |
| €1.071 | -0.041 | -3.7% | €1.068 | €1.075 | €1.064 | 0 | |
| €1.112 | -0.030 | -2.6% | €1.112 | €1.112 | €1.112 | 0 | |
| €1.142 | +0.028 | +2.5% | €1.142 | €1.142 | €1.142 | 0 |
- Ticker
- Frankfurt:8ZD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Nov 2, 2026
Closed €0.73 (+4.4%) on Nov 2, 2026
Change of company name
Nov 2, 2026
Closed €0.73 (+4.4%) on Nov 2, 2026
Next Day Disclosure Returns
Oct 30, 2026
Closed €0.699 (-2.8%) on Oct 30, 2026
Abbisko Cayman Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 28 in the last 12 months · 38 in all · newest Nov 19, 2026 · oldest 2021
- Decks
- 7 decks · latest Aug 13, 2024
Where Abbisko Cayman Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2256 和譽 · Home listing | HKEX | Hong Kong | HKD |
| LS Exchange:A3C4Y0 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A3C4Y0 | Lang & Schwarz | Germany | EUR |
| Frankfurt:8ZD · This page | Frankfurt | Germany | EUR |
| Dusseldorf:8ZD | Dusseldorf | Germany | EUR |
| Stuttgart:8ZD | Stuttgart | Germany | EUR |
Valuation
Price/book 1.6× against a median of 2.2×: 5th lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.79B HKD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.0M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Aclaris Therapeutics, Inc. · NASDAQ:ACRS | US$545.6M | US$431.3M | n/a | 67.4× | n/a | 3.3× | n/a | 0.0× | 1.42 |
| ArriVent BioPharma, Inc. · NASDAQ:AVBP | US$544.1M | US$151.2M | n/a | 30.2× | n/a | 1.4× | n/a | 0.0× | 1.18 |
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$496.9M | US$470.4M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.1M | n/a | 23.2× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| Median of the others | US$511.2M | US$316.2M | 30.2× | 2.2× | −296.9% | 0.0× | 1.58 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 19.35 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.54 · 6 analysts
- Revenue, year to Dec 2026
- 284.4M · 5 analysts
Team and board
| Officer | Role |
|---|---|
| Yao-Chang Xu | Founder & CEO |
| Jia FENG | VP, HR and Operations |
| Zhen ZHANG | CMC VP |
| Hongping Yu | Co-founder, CSO |
| Jing JI | Chief Medical Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 15, 2025 | −6.1% |
| Q1 2025 | Jun 18, 2025 · Before open | +2.9% |
| Q4 2022 | Mar 14, 2023 · After close | +6.7% |
| Q2 2022 | Sep 27, 2022 · After close | −2.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Abbisko Therapeutics — H1 2024 Earnings Presentation | Earnings | 32 slides | Aug 13, 2024 |
| Abbisko Therapeutics — FY2023 Earnings Presentation | Earnings | 38 slides | Mar 13, 2024 |
| Abbisko Therapeutics — Investor Presentation (March 2024) | Investor deck | 39 slides | March 2024 |
| Abbisko Therapeutics — H1 2023 Earnings Presentation | Earnings | 32 slides | August 2023 |
| Abbisko Therapeutics — FY2022 Earnings Presentation | Earnings | 31 slides | Mar 16, 2023 |
| Abbisko Therapeutics — H1 2022 Earnings Presentation | Earnings | 18 slides | August 2022 |
| Abbisko Therapeutics — FY2021 Earnings Presentation | Earnings | 40 slides | Mar 21, 2022 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 596.3M | 504.0M | 19.1M | 0 | 22.7M | 0 | 3.84M |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross profit | 596.3M | 504.0M | 19.1M | 0 | 22.7M | 0 | 3.84M |
| Research and development | 495.3M | 451.4M | 433.7M | 378.7M | 226.1M | 132.7M | 81.5M |
| Selling, general and administrative | 75.8M | 74.2M | 35.6M | 29.8M | 54.8M | 9.11M | 12.1M |
| Operating income | 27.2M | -21.6M | -511.1M | -497.2M | -328.2M | -153.8M | -134.1M |
| Depreciation and amortization | 22.3M | 23.6M | 18.4M | 15.8M | 11.9M | 9.49M | 8.19M |
| EBITDA | 49.5M | 1.98M | -492.7M | -481.4M | -316.3M | -144.3M | -125.9M |
| Interest expense | 3.25M | 1.61M | 2.17M | 2.69M | 959.0K | 338.0K | 523.0K |
| Income before tax | 113.4M | 78.0M | -431.6M | -495.6M | -1.81B | -706.6M | -133.9M |
| Income tax | 59.6M | 49.7M | 2.69M | -4.94M | 172.0K | -221.0K | |
| Net income | 53.8M | 28.3M | -431.6M | -498.3M | -1.81B | -706.8M | -133.7M |
| Earnings per share, basic | 0.08 | 0.04 | -0.67 | -0.80 | -7.68 | -1.01 | -0.19 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 749.3M | 289.5M | 578.1M | 2.26B | 2.55B | 617.8M | 285.6M |
| Short-term investments | 1.35B | 1.67B | 918.0K | 93.8M | 26.5M | 18.9M | 11.4M |
| Receivables | 15.0M | 47.7M | 17.8M | 9.12M | 39.0K | ||
| Current assets | 2.13B | 2.02B | 2.04B | 2.41B | 2.58B | 649.8M | 300.2M |
| Property, plant and equipment | 69.3M | 77.3M | 69.3M | 14.8M | 20.1M | ||
| Total assets | 2.35B | 2.11B | 2.12B | 2.49B | 2.65B | 666.0M | 320.2M |
| Current liabilities | 427.3M | 135.4M | 109.2M | 107.6M | 73.5M | 31.7M | 17.8M |
| Long-term debt | 0 | 1.72B | 758.0M | ||||
| Total debt | 303.6M | 24.3M | 35.7M | 45.6M | 53.8M | 4.31M | 8.90M |
| Total liabilities | 430.4M | 148.7M | 134.3M | 143.2M | 118.5M | 1.77B | 779.3M |
| Shareholders' equity | 1.92B | 1.96B | 1.98B | 2.35B | 2.54B | -1.10B | -459.0M |
| Shares outstanding | 639.8M | 649.6M | 647.2M | 620.7M | 234.9M | 702.5M | 702.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 79.3M | -12.9M | -444.7M | -343.9M | -169.7M | -117.6M | -82.8M |
| Capital spending | -5.53M | -7.40M | -12.3M | -22.7M | -12.3M | -4.03M | -3.44M |
| Free cash flow | 73.8M | -20.3M | -457.0M | -366.6M | -182.1M | -121.6M | -86.3M |
| Cash from investing | 211.9M | -196.5M | 378.5M | -216.6M | -1.46B | -11.2M | 30.1M |
| Cash from financing | 186.9M | -80.9M | -16.1M | -20.8M | 2.10B | 505.9M | 176.9M |
| Share buybacks | -96.2M | -76.3M | -12.9M | -4.05M | 1.45B | 511.0M | 182.6M |
| Change in cash | 459.5M | -288.6M | -63.8M | -422.0M | 446.1M | 332.1M | 131.8M |
Filings
All 25 filings
Cap table
Built by 6ix from Abbisko Cayman Limited’s releases
- Common shares
- 716,157,350
- Fully diluted
- 716,157,350
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 716,157,350 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 716,157,350 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Hongping Yu | Co-founder, CSO · Since at least Nov 5, 2026 |
| Jia FENG | VP, HR and Operations · Since at least Nov 5, 2026 |
| Jing JI | Chief Medical Officer · Since at least Nov 5, 2026 |
| Yao-Chang Xu | Founder & CEO · Since at least Jun 10, 2025 |
| Zhen ZHANG | CMC VP · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Abbisko Cayman Limited.